Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542848 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2GPR119MAPTLMNATP53 | |
| SCHEMBL15765542 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2GPR119MAPTLMNATP53 | |
| SCHEMBL31097522 | 0.77 | GPR119 (0.36) | SMN1; SMN2GPR119NR1H2NR1H3 | |
| SCHEMBL31097505 | 0.76 | PARP1 (0.38) | — | |
| SCHEMBL5395678 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2GPR119MAPTLMNATP53 | |
| SCHEMBL22532774 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2GPR119MAPTLMNATP53 | |
| SCHEMBL17012209 | 0.72 | ALDH1A1 (0.37) | CNR2 | |
| SCHEMBL4562314 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTLMNATP53THRB | |
| SCHEMBL5398512 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2GPR119MAPTLMNATP53 | |
| SCHEMBL2850910 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTLMNATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661435-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | SMN1; SMN2 1355/4885GPR119 52/4885MAPT 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.